Your browser doesn't support javascript.
loading
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
Berenson, James; Manges, Robert; Badarinath, Suprith; Cartmell, Alan; McIntyre, Kristi; Lyons, Roger; Harb, Wael; Mohamed, Hesham; Nourbakhsh, Ali; Rifkin, Robert.
  • Berenson J; Institute for Myeloma and Bone Cancer Research, West Hollywood, California.
  • Manges R; Investigative Clinical Research of Indiana, Indianapolis, Indiana.
  • Badarinath S; Cancer Specialists of North Florida, Jacksonville, Florida.
  • Cartmell A; Comprehensive Blood & Cancer Centers, Bakersfield, California.
  • McIntyre K; Texas Health Presbyterian Cancer Center, Dallas, Texas.
  • Lyons R; US Oncology Research and Texas Oncology, San Antonio, Texas.
  • Harb W; Horizon Oncology Research, Lafayette, Indiana.
  • Mohamed H; Bristol-Myers Squibb, Princeton, New Jersey.
  • Nourbakhsh A; Bristol-Myers Squibb, Princeton, New Jersey.
  • Rifkin R; US Oncology Research and Rocky Mountain Cancer Centers, Denver, Colorado.
Am J Hematol ; 92(5): 460-466, 2017 May.
Article en En | MEDLINE | ID: mdl-28213943
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Monoclonales Humanizados / Mieloma Múltiple Límite: Humans Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Monoclonales Humanizados / Mieloma Múltiple Límite: Humans Idioma: En Año: 2017 Tipo del documento: Article